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Introduction
Opioid abuse in the United States is a serious public health issue. Approximately 1.9 million individuals in the United States have a substance use disorder involving prescription pain relievers, and an additional 586,000 have a substance use disorder involving heroin (Centers for Disease Control and Prevention [CDC], 2015) . Women and men of all ages, including adolescents, are affected; however, according the CDC (2013), the most dramatic increase in opioid use has been among women. For the years spanning 1999 through 2010, heroin use in women increased 400%, more than double the rate in men (CDC, 2013) . In addition, women are more likely than men to be prescribed opioid pain relievers for chronic pain, to use more of them, and to use them for longer periods of time, leading to an increased risk of dependency (CDC, 2013) .
According to the Substance Abuse and Mental Health Services Administration (SAHMSA; 2014), many women who use opioids are of childbearing age. Some women with substance use disorders have an unmet need for effective contraception, thus placing them at risk for unintended pregnancy (Terplan, Hand, Hutchinson, Salisbury-Afshar, & Heil, 2015) . When women with addiction experience abrupt discontinuation of opioids during pregnancy, they may also experience poor fetal outcomes such as an increased risk of intrauterine passage of meconium and neonatal aspiration, abruptio placentae, intrauterine growth restriction, preterm labor and birth, fetal distress, or fetal demise (American College of Obstetricians and Gynecologists [ACOG] Committee on Health Care for Underserved Women& American Society of Addiction Medicine, 2016; Kocherlocota, 2014) . Further, if a woman uses opioids by injection, this increases her risk of contracting HIV, hepatitis C, injection site abscess, sepsis, and endocarditis (CDC, 2013) . All of these conditions can negatively affect maternal and fetal health outcomes.
This article focuses on the pharmacologic treatment of opioid addiction during pregnancy.
Although complete cessation of all opioid use during pregnancy is the optimal scenario, abrupt withdrawal of opioids can be harmful for both a woman and fetus (Zedler et al., 2016) . Although a variety of treatment modalities exist that include both pharmacologic and psychosocial interventions, this article addresses treatment with methadone and buprenorphine, the two most common medications used to treat opioid addiction during pregnancy.
Pharmacology
All opioids, including heroin and prescription opioid pain relievers, bind to opioid receptors in the brain. The primary receptors are mu-opioid receptors. They are well-populated in areas of the brain that perceive and regulate pain, including emotional responses to pain. Further, mu receptors are concentrated in the reward region of the brain that mediates perception of pleasure and well-being. This is strongly associated with repeated use, because an individual associates opioids with these desirable effects in the brain (Akil et al., 1984) . Receptors are also populated in the brain stem where respiration is controlled. When receptors are oversaturated with more opioids than can be processed, respiratory depression and death can occur.
Tolerance, Dependence, and Addiction
Over time, the repeated administration of any opioid will result in tolerance and dependence.
Tolerance refers to an individual's response to a drug so that he/she needs to administer more of a substance to get the desired effect. Dependence occurs after repeated use when adaptations in the brain trigger physical withdrawal symptoms if the substance is not used (Volkow & McLellan, 2016) . The time from the beginning of opioid use to dependence is highly variable, and many factors are associated with this complex phenomenon, such as type of opioid, dose, and exposure frequency. What is inevitable, however, is that with repeated exposure the adaptations in opioid receptors will result in both tolerance and physical dependence (Volkow & McLellan, 2016) . The mechanism for addiction is a very different pathway than that of tolerance and dependence. Also, although tolerance and dependence are predictable, addiction is not and occurs in only a small percentage of those who use opioids (Volkow & McLellan, 2016) .
Addiction is characterized by obsessive thinking and pronounced craving for the substance and includes a loss of inhibitory control over efforts to refrain from drug and compulsive drug taking (American Psychiatric Association, 2013) .
Treatment for Opioid Addiction in Pregnancy
Untreated opioid withdrawal in the fetus can lead to poor fetal outcomes including preterm labor, fetal growth restrictions, abruptio placentae, and intrauterine passage of meconium (ACOG Committee on Health Care for Underserved Women & American Society of Addiction Medicine, 2016; Kocherlakota, 2014) . Because of the risks associated with an untreated opioid addiction, it is recommended that all women with opioid addiction receive medication-assisted treatment, which combines behavioral therapy and medications to treat substance use disorders. Although pregnancy categories are no longer being used clinically, both methadone and buprenorphine were classified as Category C. Under the current expanded labeling system, this means that adequate studies have not been conducted in pregnant women. Animal studies suggest an increased mortality in rodent offspring when high maternal doses are given, but animal models do not necessarily predict human outcomes. Previous researchers have suggested that supervised use of opioid medications such as methadone and buprenorphine is unlikely to cause a significant teratogenic risk during pregnancy (Lo & Friedman, 2002) . More recently, researchers have suggested that opioid use during pregnancy may be linked to cardiac abnormalities, but no direct causation has been established. Multiple confounding issues such as polysubstance abuse among study participants, small sample sizes, and the observational nature of the research limits conclusive evidence of a link between opioids and congenital abnormalities (Viteri et al., 2015) .
Methadone
Methadone is an opioid agonist that is metabolized by the liver. It has a long and variable halflife, anywhere from 8 to 59 hours. It is water soluble, and it accumulates in the liver and in fatty tissue (lipophilic), and has a relatively low molecular weight. Methadone is a highly regulated Schedule II medication that can only be dispensed in a licensed methadone treatment center or clinic that has strict oversight by state and federal agencies (Wiegand et al., 2015) . There are some differences depending on in which state a clinic is located. However, in general, patients must go to their treatment center daily between specified hours to receive their prescribed dose of methadone. There are some provisions for take-home medications, and these are strictly monitored with clear guidelines, but they are not often used with pregnant women. Methadone is dispensed via an electronic dispensing mechanism by a licensed practical nurse or a registered nurse and is monitored by a physician, physician's assistant, or advanced practice registered nurse; counseling is a required part of treatment.
The use of methadone as a treatment for opioid addiction during pregnancy has been the standard of care since the 1970s. The risks of methadone use in pregnancy are not well documented despite almost 50 years of use. Broussard et al. (2011) documented the risks of short-acting opioids with a small relative risk in congenital malformations but not absolute risk, and only in short acting opioids; however, no data on dose and frequency of use were reported. Despite low rates of teratogenic outcomes, it is widely understood that neonatal opioid withdrawal syndrome occurs in up to 94% of newborns born to women who use methadone (Kocherlakota, 2014) .
If a woman begins methadone while pregnant, the dosage is typically initiated at 10 to 30 mg per day and titrated until she is asymptomatic, meaning she is having no signs or symptoms of opioid withdrawal. Although there are no universal recommendations, it is understood that pregnant women should be closely monitored, usually monthly, particularly in the third trimester (ACOG Committee on Health Care of Underserved Women& American Society of Addiction Medicine, 2016). There is no ceiling for methadone dosing in pregnancy, and there does not appear to be a correlation between methadone dose and neonatal opioid withdrawal syndrome severity (Kocherlakota, 2014 Methadone also has the potential to interact with other medications. Methadone is mostly metabolized in the liver via the N-demethylation by the cytochrome P450 (CYP) 3A4 system, which varies among individuals and accounts for differences in methadone metabolism. In addition, the CYP2D6 and probably CYP1A2 systems are also involved in methadone metabolism, and treatment with other drugs may be influenced, including psychotropic drugs, antibiotics, anticonvulsants, and antiretroviral drugs, which are also CYP2A4 inducers. If a woman is already taking methadone before pregnancy, her dosage is likely to be increased during pregnancy because the bioavailability of methadone is reduced in pregnancy. Although pregnancy is known to affect hepatic drug metabolism, the underlying mechanisms are not well understood for all drugs, including methadone.
Physiologic changes during pregnancy that may affect drug-metabolizing enzymes include elevated concentrations of estrogen, progesterone, placental growth hormones, and prolactin. This is particularly true in late pregnancy, when binding of methadone to plasma proteins decreases plasma levels. Although the mechanism is poorly understood, it is thought that elevated levels of progestin can affect transporter metabolizing enzymes and influence hepatic drug metabolism (Hyunyoung, 2010; Kreek, 1983) . Therefore, women need to be monitored more carefully during pregnancy, at least monthly, to make sure their dosage is adequate and that they are not experiencing cravings and are attending their prenatal appointments.
Buprenorphine
Buprenorphine, a Schedule III medication, is a partial agonist at the mu receptors and antagonist at kappa receptors. It is an opioid agonist-antagonist and currently can be prescribed only by accredited physicians who have undergone specific credentialing and training. Additionally, it is the only opioid approved for the treatment of opioid dependence in an office-based setting. The U.S. Food and Drug Administration has approved both single and combination buprenorphine products. The combination products, which contain buprenorphine and naloxone, come in sublingual/buccal transmucosal films and tabs. The naloxone included in the combination product has poor bioavailability when taken sublingually or orally and is included to prevent diversion and abuse. It is activated and causes withdrawal symptoms when crushed or injected.
At the time of this writing, buprenorphine products cannot be prescribed by midlevel providers such as nurse practitioners, certified nurse-midwives, and physician assistants; however, there is legislation pending that may lift this restriction in the near future.
Although methadone is the standard of care for medication-assisted treatment of pregnant women in the United States, buprenorphine is also used to treat opioid addiction during pregnancy. Buprenorphine has been approved by the U.S. Food and Drug Administration for medication-assisted treatment in the United States since 2002. There is emerging evidence supporting the use of single-product buprenorphine, rather than combination products, for treatment of pregnant women (Soyka, 2013) . The use of naloxone with buprenorphine in pregnant women is generally not recommended, because theoretically naloxone may cross the placenta and precipitate withdrawal in the fetus (Hyunyoung, 2010) . However, researchers who conducted a recent review of buprenorphine and buprenorphine/naloxone concluded that there were no significant differences in adverse maternal and fetal outcomes between buprenorphine monotherapy and buprenorphine/naloxone combination therapy (Lund et al., 2013) .
Differences Between Treatment With Methadone Versus Buprenorphine
Both methadone and buprenorphine have a place in the treatment of pregnant women with opioid addiction (Holbrook, 2015) . A major barrier to treatment during pregnancy includes a lack of treatment centers that can accommodate treatment of pregnant women (Willson & Thorp, 2008) , and this may be a factor when selecting a therapy. For example, if there is no health care provider who is willing to prescribe buprenorphine to pregnant women or no certified provider in the geographic area, methadone may be the only option. Regardless of what medication they are using, pregnant women should be given treatment priority, especially if provider panels and spaces in treatment centers are limited.
In general, there are some fundamental differences between the two treatment regimens for all women, as well as caveats to consider when treating pregnant women (see Table 1 ). Because methadone is a highly controlled and regulated medication, it can be dispensed only in a licensed facility when prescribed for opioid abuse. In most cases, this will require that the individual go to a clinic daily, although take-home medication privileges can be earned for some people who are receiving treatment. However, pregnancy in and of itself does not meet criteria for take-home treatment. Buprenorphine is prescribed in an office environment and typically requires a minimum of monthly visits to an authorized prescriber.
From a safety perspective, methadone has drug interactions and can cause corrected QT interval prolongation and sedation. Buprenorphine carries some safety concerns as well, including drug interactions and potential for abuse, particularly during pregnancy, and buprenorphine combination products are not recommended in pregnancy so as to avoid fetal exposure to the naltrexone that is present in them. However, potential advantages of buprenorphine over methadone include a lower risk of overdose, fewer potential drug interactions, the availability of office visits, and the potential for less severe symptoms of neonatal opioid withdrawal syndrome in the neonate (Kocherlokata, 2014). Potential disadvantages include the possible altered hepatic function, potential for increased dropout rates due to dissatisfaction with the drug, and decreased adherence compared with methadone regimens (Fowler et al., 2013) .
Methadone presents some challenges as well. There is a less flexible treatment regimen than buprenorphine, which can be prescribed monthly like most other medications. Compared with buprenorphine, methadone may have an increased potential for abuse and overdose, for more drug interactions, and for a more prolonged course of neonatal opioid withdrawal syndrome (Holbrook, 2015; Wiegand et al., 2015; Zelder et al., 2016) . Researchers have also reported higher doses of medication required to treat neonatal opioid withdrawal syndrome in neonates born to mothers using methadone over buprenorphine (Jones et al., 2010) . Regardless of which medication is chosen, there are federal guidelines that apply to both medications (Substance Abuse and Mental Health Services Administration, 2015). Generally, policies include the initial dose for a newly admitted pregnant woman and effective dosing protocols. Women are encouraged to continue treatment postpartum; however, there is currently a lack of data to measure adherence to this recommendation.
Neonatal Considerations
Neonatal opioid withdrawal syndrome, a transient and curable condition, occurs in neonates when a pregnant woman takes opioid drugs. These can include both illegal and legal substances such as heroin, codeine, oxycodone, fentanyl, morphine, methadone, or buprenorphine (Kocherlakota, 2014) . Because these drugs pass through the placenta to a fetus, a neonate can be addicted along with the mother. When a newborn stops receiving the opioid via maternal transmission after birth, he or she can exhibit symptoms of withdrawal, which may include tremors, poor feeding, vomiting, irritability, disrupted sleep, fever, and inability to be consoled and soothed. Signs and severity of withdrawal are variable and typically begin 1 to 3 days after birth, but they may occur up to 1 week after birth. Symptom severity varies among individuals and is contingent upon many different factors, including which drug was used, how much of it, how the body metabolized it, and duration of use (Akil et al., 1984) . Gestational age at birth also affects the severity. Because of the immaturity of all systems, premature infants have more severe symptoms (Kocherlakota, 2014) .
Breastfeeding
Breastfeeding has specific benefits for women and newborns during treatment for opioid abuse.
Breastfeeding promotes bonding and may also help decrease symptoms associated with neonatal opioid withdrawal syndrome (Welle-Strand et al., 2013) . Women receiving medication-assisted treatment in the postpartum period are encouraged to breastfeed their infants regardless of their opioid dosage (ACOG Committee on Health Care for Underserved Women & American Society of Addiction Medicine, 2016; Tsai & Doan, 2016) . However, there is a need to understand that medication is excreted in breast milk and that if there is an abrupt cessation, a newborn may experience symptoms of opioid withdrawal if the mother is receiving high doses of medicationassisted treatment. As infants are weaned from breast milk and gradually introduced to solids during the natural course of infant feeding, they are then weaned off of the medication as well.
Implications for Nursing Practice
Regardless of whether nurses interact with women during the prenatal period, during labor and birth, or during the postpartum period, nonjudgmental and supportive care and communication are essential. Pregnant women with substance use disorders are often judged harshly and stigmatized by family, friends, society, and even health care providers, who may see the opioid abuse as a weakness that needs to be punished rather than a health condition that needs to be treated (Jones et al., 2010) . In some states, opioid abuse during pregnancy is criminalized, further adding to stigma, suspicion of health care providers, removal of children from the home, and reluctance to enter care (Kremer & Arora, 2015; Martin & Finlayson, 2015) . When a trusting relationship is built between women and their providers, there is a greater chance of accurate disclosure of drug use, increased attendance at prenatal appointments, and greater adherence to opioid treatment (Krans, Cochran, & Bogen, 2015) .
Intrapartum and postpartum management require that health care providers, including nurses who are providing direct care, know what pharmacologic treatment a woman is receiving.
Because methadone is not prescribed in a traditional sense, using a prescription monitoring program or contacting the patient's pharmacy will not reveal any information related to methadone. However, if a woman is being treated with buprenorphine, her medical, dosage, and prescription histories would be readily available. Careful documentation by prenatal care providers is essential so that information is available to those providing care during the Ideally, women should be working with their obstetric health care providers and truthfully disclosing their substance use. In general, obstetric providers do not treat a woman's drug addiction, and similarly, an addiction specialist will not treat pregnancy-related issues.
Therefore, it is important that frequent communication be maintained between the woman's obstetric care provider and the addiction medicine provider to coordinate care. The federal confidentiality law 42 CFR Part 2 applies to addiction treatment providers and, according to the law, patient information release forms with specific language regarding substance use are required (United States Government Publishing Office, 2016).
Nurses who work with women receiving treatment with either methadone or buprenorphine are in a position to provide ongoing education in addition to support and nonjudgmental care.
Although treatment is dispensed in an office or clinic setting under supervised conditions, women should be advised of serious adverse effects, especially respiratory depression, if taken concurrently with central nervous system depressants. These include alcohol, other narcotic medications, sedatives, and hypnotic sleep aids. Using other medications with abuse potential or using illicit drugs during treatment places a woman at risk for relapse. Medication lists should be reviewed with women at each visit.
Conclusion
Opioid addiction is a chronic long-term brain disease that requires treatment in all populations, including pregnant women. Medication-assisted treatment has been, and continues to be, the standard of care in women presenting with opioid addiction, including addiction during pregnancy. The treatment benefits far outweigh the risks in both the infant and the mother if the addiction is not addressed. The benefits include the prevention of maternal and fetal risks associated with active opioid use such as infection, inconsistent prenatal care, IUGR, preterm birth, and prolonged neonatal withdrawal. Care for pregnant women with opioid addiction should include a combination of pharmacologic and psychosocial interventions delivered in a supportive and nonjudgmental environment. 
